Novartis sends second wagon after KRAS gold rush

Joining the barrage of companies digging headfirst into the newly opened KRAS mine, Novartis has announced a multiyear agreement with Sixth Element Capital and the UK Beatson Institute for Cancer Research to develop small molecules identified by the institute’s drug discovery unit.